ISRCTN11769612 https://doi.org/10.1186/ISRCTN11769612

Effects of lifestyle changes in an obese metabolically healthy elderly population

Submission date
11/11/2021

Recruitment status
No longer recruiting

Registration date
29/11/2021

Overall study status
Completed

Last Edited
20/12/2023

Condition category
Nutritional, Metabolic, Endocrine

[_] Prospectively registered
[X] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol

Background and study aims
Metabolically Healthy Obese individuals (MHO) are special, seemingly protected from the cardiometabolic disorders associated with excess body fat. The aim of this study is to test whether the change of lifestyle by promoting physical exercise and recommendations of a healthy Mediterranean-style diet (without caloric restriction) in elderly MHO is associated with changes in insulin sensitivity and metabolomic mechanisms.

Who can participate?
Persons aged over 65 years, with a body mass index of 30-40 kg/m² and one or fewer common health issues associated with obesity.

What does the study involve?
Participants will be encouraged to follow a Mediterranean diet based on the Trichopoulou index and practice regular adapted physical activity for 24 months. During the follow-up, 4 visits are planned: baseline and at 4, 12, and 24 months.

What are the possible benefits and risks of participating?
There are no other potential risks from participating in this study other than discomfort from taking blood samples. The potential benefits derive from following a healthy Mediterranean diet and practicing adapted physical activity, which have been shown to prevent cardiovascular disease.

Where is the study run from?
Regional University Hospital of Malaga (Spain)

When is the study starting and how long is it expected to run for?
July 2018 to March 2022

Who is funding the study?
Institute of Health Carlos III (Spain)

Who is the main contact?
Dr. M Rosa Bernal-Lopez, robelopajiju@yahoo.es.

Contact information

Type(s)
Scientific

Contact name
Dr M Rosa Bernal-López

ORCID ID
http://orcid.org/0000-0002-0238-0890

Contact details
Internal Medicine Department
Regional University Hospital of Malaga
Instituto de Investigación Biomédica de Málaga (IBIMA)
Avda. Hospital Civil, s/n.
Malaga
Spain
29009
+34 951290346
robelopajiju@yahoo.es

Type(s)
Public

Contact name
Dr M Rosa Bernal-López

Contact details
Internal Medicine Department
Regional University Hospital of Malaga
Instituto de Investigación Biomédica de Málaga (IBIMA)
Avda. Hospital Civil, s/n.
Malaga
Spain
29009
+34 951290346
robelopajiju@yahoo.es

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number

ClinicalTrials.gov number
Nil known

Secondary identifying numbers
PI18/00766

Study information

Scientific Title
Obese metabolically healthy elderly population: -omic studies (epigenetics, metabolomics, metagenomics) and its relationship with environmental pollutants

Study objectives
H1. It is postulated that the maintenance and/or weight loss produced by a change in lifestyle, mediated by changes in dietary habits and physical activity, and undertaken at the community level in the elderly Metabolically Healthy Obesity (MHO), will improve insulin sensitivity, compared to the non-responder group. Environment factors such as diet are able to modify the profile of epigenetic changes and, consequently, influence the development of obesity-associated diseases such as insulin resistance.
H2. It is postulated that epigenetic modifications (on histones and in the promoter region) in genes involved in insulin resistance in obesity (epiobesigenes) are responsible for the development of the same, through the regulation of gene expression of genes regulating expansion ability, adipose tissue differentiation, adipogenesis, lipogenesis and inflammation.
H3. It is postulated that the components of the microbiota have an immune function, a trophic function and digestive function. For this, interindividual variability exists depending on the composition of the flora, which can modify the energy value of food.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Approved 26/07/2018, Comité de Ética de la Investigación Provincial de Málaga (Hospital Regional Universitario de Málaga, Avnda. Carlos Haya s/n, Pabellón A, 7º planta, Málaga, Spain; +34 951 29 19 77; gloria.luque.exts@juntadeandalucia.es), ref: PI18/00766-260718

Study design
Interventional cross-sectional open study

Primary study design
Interventional

Secondary study design
Non randomised study

Study setting(s)
Hospital

Study type(s)
Other

Participant information sheet
See study outputs table

Health condition(s) or problem(s) studied
Lifestyle intervention in metabolically healthy obese older adults

Interventions
Participants will be encouraged to follow a Mediterranean diet advised by a nutritionist based on the Trichopoulou index and practice regular adapted physical activity for 24 months. The recommended caloric intake is 1500-1750 kcal/day, distributed as follows: 30% from fats (5-8% from saturated fatty acids, 15-18% from monounsaturated fatty acids, 5-8% from polyunsaturated fatty acids and <300 mg of cholesterol/day), 55% from carbohydrates (<10% from simple sugars, 40% from complex sugars and low glycemic index) and 15% from protein. The recommended Mediterranean diet is based on the Trichopoulou criteria, prioritizing olive oil as the main cooking fat, consuming poultry or rabbit meat preferably rather than red meat and encouraging the consumption of fish, fruits, legumes and vegetables. Similarly, participants are encouraged to practice daily physical activity adapted to their age and physical condition, following the internationally-accepted physical activity guidelines (Physical Activity Guidelines for Americans. Chapter 5. Available at https://health.gov/our-work/physical-activity/current-guidelines). The intervention will last 24 months. Visits will be made at baseline and then at 4 and 12 months to reinforce the intervention and monitor the study variables and at 24 months to monitor the study variables for the last time. Lipid profile, inflammatory biomarkers (hsPCR, IL6, TNFa, fibrinogen) and adipokines (adiponectin, leptin) will be analyzed. Epigenetic (methylation), metabolomic, and metagenomic (gut microbiota) studies will be carried out and their possible relationship with different environmental pollutants will be analyzed.

Intervention Type
Behavioural

Primary outcome measure
The primary outcome is a composite outcome where the researchers will analyze the effectiveness of a multidisciplinary and multicomponent intervention carried out in the community setting, aimed at modifying the lifestyle (use of a Mediterranean diet and promotion of physical activity) to prevent the incidence of cardiometabolic alterations in elderly healthy metabolically obese subjects. This has been quantified as an improvement in Mediterranean diet adherence through food frequency questionnaires (baseline and 4, 12 and 24 months) and improvement in physical activity intensities, measured by accelerometry (minutes/day).

1. Nutritional assessment and monitoring: food intake analyzed using questionnaires at baseline and at 4, 12 and 24 months:
1.1. A non-consecutive, 3-day dietary record (two workdays and one weekend day), containing detailed information about food composition and cooking recipes over 72 hours
1.2. A food frequency questionnaire (number of times/day, number of days/week, number of days/14 days, number of days/month, rarely, or never)
1.3. Adherence to Mediterranean diet assessed by a validated 14-item food consumption frequency questionnaire
2. Physical activity monitored using a GENEActiv Actigraph GT3X+ accelerometer at baseline and at 4, 12 and 24 months. The accelerometer should be worn under the chest with a tight elastic belt to ensure close contact with the body. Recordings are made every day for at least 7 days (weekdays and the weekend) to take their hours of physical activity and sleep, except during water activities. Physical activity is also evaluated using the Rapid Assessment of Physical

Activity (RAPA) questionnaire, a validated 7-item questionnaire at baseline and at 4, 12 and 24 months

Secondary outcome measures
1. Anthropometric variables measured by trained personnel at baseline and at 4, 12 and 24 months:
1.1. Weight measured using an electronic scale: TANITA Body Composition Analyzer. Type TBF-300 MA. (TANITA Corporation; 1-14-2 Maeno-cho, Itabashi-ku. Tokio, Japan)
1.2. Height measured with no shoes using a wall stadiometer (Stadiometer Barys Electra Model. 511-300-A0A. ASIMED)
1.3. BMI calculated by dividing weight (kg) by height squared (m^2)
1.4. The waist/hip index (WHI) calculated as the ratio of abdominal circumference (at the level of the mid-point between the anterosuperior iliac crest and the last costal arch, parallel to the ground and upon exhalation) and hip, both in cm
1.5. Blood pressure measured with a validated automated electronic sphygmomanometer (OMRON M7 (HEM-780-E, OMRON Healthcare Co. Ltd, Kyoto, Japan) after 5 minutes of rest while the participant is in a seated position
2. Serum adipokine and inflammatory biomarkers levels (IL-6 and TNFa) measured using an enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Inc., Minneapolis, MN, USA) on blood samples collected after an overnight fast at baseline and at 4, 12 and 24 months
3. High-sensitivity CRP levels measured using ELISA (DRG Instruments GmbH, Germany) on blood samples collected after an overnight fast at baseline and at 4, 12 and 24 months

Overall study start date
26/07/2018

Completion date
31/03/2022

Eligibility

Key inclusion criteria
1. Aged >65 years
2. BMI ≥30-<40 kg/m^2
3. One or none of the following four cardiometabolic disorders:
3.1 Systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg
3.2 Triglycerides ≥150 mg/dl
3.3 HDL-C <40 mg/dl in men and <50mg/dl women
3.4 Fasting blood glucose ≥100 mg/dl, following the WHO criterion of MHO

Participant type(s)
Healthy volunteer

Age group
Senior

Lower age limit
65 Years

Sex

Both

Target number of participants
150

Total final enrolment
169

Key exclusion criteria
1. Diabetes
2. Hypertension
3. Previous cardiovascular disease (coronary, cerebrovascular or peripheral; aortic aneurysm, heart failure)
4. Severe associated disease (advanced organ failure, dementia, cancer)
5. Immobilized or terminally ill individuals
6. Alcoholism or drug addiction
7. Severe psychiatric illness
8. Weight loss ≥5 kg in the last 6 months of unknown cause.

Date of first enrolment
01/11/2018

Date of final enrolment
10/03/2020

Locations

Countries of recruitment
Spain

Study participating centre
Regional University Hospital of Málaga
Avda. Carlos Haya, s/n
Málaga
Spain
29007

Sponsor information

Organisation
Instituto de Investigación Biomédica de Málaga

Sponsor details
Calle Dr. Miguel Díaz Recio, 28
Malaga

Spain
29010
+34 951440260
info@ibima.eu

Sponsor type
Research organisation

Website
http://www.ibima.eu/

ROR
https://ror.org/05n3asa33

Funder(s)

Funder type
Government

Funder Name
Instituto de Salud Carlos III

Alternative Name(s)
SaludISCIII, InstitutodeSaludCarlosIII, Instituto de Salud Carlos III | Madrid, Spain, Carlos III Institute of Health, Institute of Health Carlos III, Carlos III Health Institute, ISCIII

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
Spain

Results and Publications

Publication and dissemination plan
Planned publication in a high-impact peer-reviewed journal. The study protocol and statistical analysis plan are not published, but they are available upon request from María Rosa Bernal-López (robelopajiju@yahoo.es).

Intention to publish date
30/10/2022

Individual participant data (IPD) sharing plan

The datasets generated during and analysed during the current study are available upon request from María Rosa Bernal-López (robelopajiju@yahoo.es). Data is already partially available and will be stored for the next 10 years. Each participant gave their written consent and data was anonymized by giving each participant an identification number code. Data are available if the study results need to be checked.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet			15/11/2021	No	Yes
Results article		01/09/2022	10/10/2022	Yes	No
Results article		13/11/2021	10/10/2022	Yes	No
Results article		09/06/2022	10/10/2022	Yes	No
Protocol (other)		09/06/2022	20/12/2023	No	No